InnoCare Pharma Ltd. logo

InnoCare Pharma Ltd. (INCPF)

Market Closed
10 Aug, 20:00
OTC PINK OTC PINK
$
1. 55
0
0%
$
2.32B Market Cap
- P/E Ratio
- Div Yield
1,000 Volume
0 Eps
$ 1.55
Previous Close
Add Transaction
Day Range
1.55 2.05
Year Range
1.55 3.26
Want to track INCPF and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

INCPF closed yesterday higher at $1.55, an increase of 0% from Friday's close, completing a monthly increase of 0% or $0. Over the past 12 months, INCPF stock lost -24.3902%.
INCPF is not paying dividends to its shareholders.
The last earnings report, released on Mar 26, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 6 different exchanges and in various currencies, with the primary listing on HKEX (HKD).

INCPF Chart

People also search for

Bangkok Dusit Medical Services Public Company Limited Unsponsored ADR
$ 23.3
0%
Bangkok Dusit Medical Services Public Company Limited
$ 0.56
0%
Makita Corporation Sponsored ADR
$ 34.2
+0.411%
FNCL 2.5 2013 USB Float
$ 50,000
0%
Alibaba Health Information Technology Ltd.
$ 8.85
0%

InnoCare Pharma Ltd. (INCPF) FAQ

What is the stock price today?

The current price is $1.55.

On which exchange is it traded?

InnoCare Pharma Ltd. is listed on OTC PINK.

What is its stock symbol?

The ticker symbol is INCPF.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 2.32B.

Has InnoCare Pharma Ltd. ever had a stock split?

No, there has never been a stock split.

InnoCare Pharma Ltd. Profile

Biotechnology Industry
Healthcare Sector
Dr. Jisong Cui Ph.D. CEO
OTC PINK Exchange
KYG4783B1032 ISIN
China Country
1,176 Employees
- Last Dividend
- Last Split
- IPO Date
InnoCare Pharma Ltd. is a leading biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies for cancer and autoimmune diseases. Headquartered in Beijing, China, InnoCare Pharma plays a significant role in the healthcare sector by advancing innovative treatments that address unmet medical needs. The company's robust pipeline emphasizes targeted therapies and small molecule drugs, aiming to improve patient outcomes with effective and safe medical solutions. InnoCare Pharma's operations span research and development, clinical trials, and eventual product commercialization, impacting both domestic and international markets. A cornerstone of its strategy is leveraging strategic partnerships and cutting-edge technology to accelerate drug discovery processes and broaden its therapeutic portfolio. Through its commitment to high-quality innovation, InnoCare Pharma contributes significantly to the biotech industry, positioning itself as a vital player in addressing pressing global health challenges. Its extensive research initiatives and collaborations underscore its market significance, aimed at paving the way for breakthroughs in the treatment of serious diseases.

Contact Information

Address: Building 8
Phone: 86 10 6660 9999